eligibility_summary
Eligible: adults 18–80 with histologically confirmed CD20+ primary CNS large B‑cell lymphoma or primary vitreoretinal lymphoma (WHO 5th), life expectancy >3 months, adequate renal function (CCR ≥50 mL/min or eGFR ≥60), coagulation (INR/aPTT ≤1.5× ULN), LVEF ≥50%, consent. Exclude: pregnant/lactating, active HBV/HCV, immunodeficiency, CHF ≤6 mo/NYHA III–IV/LVEF<50, drug allergy, other malignancy, severe infection, substance abuse, or deemed unsuitable.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: Zanubrutinib + rituximab with high‑dose methotrexate (or temozolomide if MTX‑intolerant), responders continue zanubrutinib maintenance for 1 year. Mechanisms and drug types: Zanubrutinib is an oral, selective covalent BTK inhibitor (small molecule) that blocks B‑cell receptor (BCR) signaling to suppress survival/proliferation of lymphoma B cells. Rituximab is an anti‑CD20 monoclonal antibody that depletes malignant B cells via complement activation, ADCC, and apoptosis. Methotrexate is an antimetabolite (DHFR inhibitor) that impairs folate‑dependent thymidylate/purine synthesis, inhibiting DNA/RNA synthesis (high dose for CNS penetration). Temozolomide is an oral alkylating agent that methylates DNA (notably O6‑guanine), inducing DNA damage and apoptosis. Targets: CD20+ malignant B cells in primary CNS large B‑cell lymphoma, key pathways include BTK/BCR signaling and nucleotide synthesis/DNA integrity.